APLS FY2025 EPS Estimate Lowered by Cantor Fitzgerald

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for Apellis Pharmaceuticals in a research note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will post earnings per share of ($2.38) for the year, down from their previous forecast of ($0.94). Cantor Fitzgerald currently has a "Overweight" rating and a $44.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share.

APLS has been the topic of a number of other research reports. Wedbush dropped their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Mizuho dropped their price target on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday. HC Wainwright restated a "buy" rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Royal Bank of Canada lowered their target price on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Finally, Wells Fargo & Company cut their price target on Apellis Pharmaceuticals from $30.00 to $26.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. Nine investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Apellis Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $40.42.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock traded down $0.58 during trading hours on Monday, reaching $16.70. 2,649,931 shares of the stock traded hands, compared to its average volume of 2,225,421. Apellis Pharmaceuticals has a one year low of $16.42 and a one year high of $43.99. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -8.23 and a beta of 0.73. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The company has a 50 day moving average price of $20.66 and a 200 day moving average price of $26.85.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). The business had revenue of $149.90 million during the quarter, compared to analysts' expectations of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals's quarterly revenue was down 3.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.54) EPS.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its holdings in shares of Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after purchasing an additional 758 shares in the last quarter. Signaturefd LLC lifted its position in Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after purchasing an additional 918 shares during the last quarter. Assetmark Inc. grew its stake in shares of Apellis Pharmaceuticals by 3,938.7% in the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company's stock worth $27,000 after buying an additional 1,221 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Apellis Pharmaceuticals in the 4th quarter worth $83,000. Finally, US Bancorp DE increased its holdings in shares of Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after buying an additional 1,327 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Insider Activity

In other news, General Counsel David O. Watson sold 5,569 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares in the company, valued at $3,482,123. This trade represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 6.50% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).